Shrink Nanotechnologies said that CellAlign allows for the structured alignment of biological tissues, particularly tissues which naturally grow in a linear fashion (like cardiac or nerve tissue).
CellAlign’s key feature is a micro-fabricated substrate with non-periodic (or random) linear patterned grooves that allow for the alignment of cells along a single axis. The alignment condition is paramount for many cellular processes and is most physiologically relevant to biological tissue.
Mark Baum, president of Shrink Nanotechnologies, said: “CellAlign has the potential to grow sheets of living tissues that may one day act as ‘band-aids’ to patch and repair, and possibly regenerate, damaged or diseased organs.
“Clinical practices and medical specialties are increasingly turning to cellular-based therapies to solve some of the world’s most perplexing health maladies. As our intellectual property position improved with CellAlign, future licensing potential represents a significant market opportunity for Shrink.”
Shrink Nanotechnologies owns and develops proprietary and patent-pending nano-sized technologies, components and product systems.
